Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
|Videos|January 18, 2018
Pseudomonas Infections: Mortality & Health Care Costs
Author(s)Contagion® Editorial Staff
Marin H. Kollef, MD, discusses the mortality and health care costs associated with Pseudomonas infections.
Advertisement
Marin H. Kollef, MD, professor of medicine and Virginia E. & Sam J. Golman chair of the Respiratory Intensive Care department of Washington University School of Medicine, discusses the mortality and health care costs associated with Pseudomonas infections.
Interview transcript (modified slightly for readability):
“The mortality and health care costs associated with Pseudomonas infections are quite significant. Pseudomonas is one of the more common nosocomial infections that we see in the hospitalized patient.
The mortality associated with it depends on the type of infection, but can vary anywhere from 10% to 15% to as high as 30% or 40% when we’re talking about bacteremic patients who are in septic shock, particularly if they are neutropenic or if they have or if they have other immunosuppressed systems that are in place.
From a health care cost perspective, we know that any nosocomial infection increases the length of stay within the hospital Pseudomonas in particular, if it’s not treated correctly upfront, can have an even greater length of stay associated with that particular situation. And so, it’s not just the organism, it’s also the host factors and whether or not the infection is treated correctly.”
Advertisement
Related to this article
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events
4
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
5